|View printer-friendly version|
Cidara Therapeutics Announces Data from Studies of Novel Antifungal CD101 to be Presented at ACCP and IDWeek Annual Meetings
Data Highlight Safety and Efficacy of CD101 IV and CD101 Topical for the Treatment of Fungal Infections
A total of five presentations will highlight the unique attributes of
CD101, Cidara’s lead antifungal drug candidate and the only long-acting
antifungal in the echinocandin class. In
“These presentations showcase the breadth and depth of our work to
advance CD101, a compound with demonstrated potential to address the
urgent unmet need for new and effective antifungal agents," said
Details of the Cidara ACCP and IDWeek 2016 presentations are as follows:
ACCP 2016 Presentations
- 258: Safety and Pharmacokinetics of Single and Multiple Doses of CD101 IV: Results from Two Phase 1 Dose-Escalation Studies; T. Sandison, et. al.
- 261E: Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters; E.A. Lakota, et. al.
IDWeek 2016 Presentations
- 1625: Activity of a Long Acting Echinocandin (CD101) and Comparator Antifungal Agents Tested Against Contemporary Worldwide Invasive Fungal Isolates; M. Pfaller, et. al.
- 1639: Efficacy of Topical CD101, a Novel Echinocandin, Against Azole-Resistant Candida albicans in Rat Vulvovaginal Candidiasis; V. Ong, et. al.
- 1994: PK-PD Target Attainment Analyses to Support the Selection of Extended Interval CD101 Dosing Regimens; E.A. Lakota, et. al.
Copies of these presentations and posters will be available on the Cidara website following the meetings: http://www.Cidara.com/
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, CD101, through Phase 2
studies in two indications and developing CD201, its bispecific
antimicrobial immunotherapy, for the treatment of multi-drug resistant
bacterial infections. CD101 IV has enhanced potency and is the only
once-weekly therapy intended for the treatment and prevention of
life-threatening invasive fungal infections. CD101 topical is the first
and only agent of its class being studied for the treatment and
prevention of vulvovaginal candidiasis (VVC), a prevalent mucosal
infection. CD201 is the first drug candidate selected from Cidara’s
novel Cloudbreak™ platform, the first immunotherapy discovery platform
designed specifically to create compounds that direct a patient's immune
cells to attack and eliminate bacterial, fungal or viral pathogens.
Cidara is headquartered in
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effectiveness, safety, long-acting nature,
anticipated human dosing and other attributes of CD101 IV and CD101
topical, and their potential to treat infections, as well as the
intended design of current and future Cloudbreak compounds. Risks that
contribute to the uncertain nature of the forward-looking statements
include: the success and timing of Cidara’s preclinical studies and
clinical trials; regulatory developments in